Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Pump's daily trading recs, emphasis on short selling -- Ignore unavailable to you. Want to Upgrade?

To: Michail Shadkin who wrote (5071)	8/7/2001 11:41:30 PM
From: Jose Matos	Read Replies (1) \| Respond to of 6873

Here's one to look at as a good short candidate: ENZN- Enzon, Inc. is a biopharmaceutical company that develops, manufactures and markets enhanced therapeutics forlife-threatening diseases through the application of its proprietary technologies. For the 9 months ended 3/31/01, revenues rose 70% to $21.1M. Net income applicable to Common totaled $8.2M vs. a loss of $5.3M. Results reflect increased ONCASPAR sales and royalties earned on sales of PEG-INTRON, and the absence of an inventory write-off. NJ based biotech company with a whopping 90 employees. $60 close, 405 PE, Price/Sales 108, Market cap $2.5B At this price and valuation, you'd think they just cured cancer. The chart looks like it's about to head down and quickly. Any comments? I'm hitting it tomorrow. Jose